Wed, May 7, 8:45 PM (11 days ago)
**Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $695.42 million, up 5.5% YoY. - **Profit Margins:** Gross margin at 36.8%, up from 36.1% YoY. Operating margin at 14.4%, up from -1.6% YoY. - **Net Income:** $24.62 million, a significant improvement from a loss of $81.68 million YoY. - **Cash Flow:** Positive operating cash flow of $7.41 million, a reversal from a negative $4.41 million YoY. **Segment Performance:** - **Affordable Medicines:** Revenue up 6.0% to $414.71 million, operating income at $110.79 million. - **Specialty:** Revenue up 2.9% to $108.30 million, operating income at $14.99 million. - **AvKARE:** Revenue up 6.0% to $172.42 million, operating income at $12.91 million. **Key Trends & Uncertainties:** - Growth driven by new product launches and strong volume growth. - Increased R&D and SG&A expenses due to product launches and legal costs. - Legal settlements and contingent liabilities pose financial risks. - Dependence on a limited number of customers and suppliers. - Global economic and political uncertainties may impact operations. **Future Operations & Impact:** - Plans to invest $120 million in capital expenditures for 2025. - Expansion into international markets and new product development. - Continued focus on cost management and operational efficiencies. - Potential impact from tariffs, trade policies, and regulatory changes.